Interpretation of the total market value of Chinese medicine: Invisible Champion turned out to be Baekje Divine?

January 23 Pharmaceutical Market value of what will happen if divided according to geographical? The number of enterprises and market capitalization are the top of the economically developed, private economy is active, such as 'north to deep' these cities not only have more than A good economic foundation, more importantly, the entire industrial ecosystem has also played a strong supporting role to support enterprises bigger and stronger. Also of note is that as Lianyungang, Taizhou, Puning, Zhangzhou, East Azerbaijan such body The smaller cities, with one or two head geese, are both the major local taxpayers and the local economic eco-system.

Recently, the East Choice of wealth data released the Chinese listed companies market value 500 list, of which 42 medicine class enterprise Among them.

E Pharmaceuticals Managers By combing the registration of nearly 300 listed pharmaceutical companies, it found that Lianyungang in Jiangsu Province not only has Hengrui (market capitalization of 194.3 billion yuan) and Chia Tai Chun Ching (a major asset of Hong Kong-listed China Biopharmaceutical (with a market capitalization of 85.9 billion yuan)), Kang margin of medicine (the market value of 8200000000) and so on, there are not listed on the predators Jiangsu Hao Sen and so on, beyond the 'deep north', is the stealth champion in the entire market value of the map.

In the first place, Hengrui Pharmaceutical is still doing my part to the total market capitalization of 194.3 billion yuan closing 2017 stock market, compared with 2016, Hengrui Pharmaceutical's market value in a year turned nearly doubled, an increase of up 81.92% .But the market value of the fastest rising champion, not Hengrui, and blossoms in Nasdaq-listed Baekje Shenzhou to 318.24% increase, 29.1 billion yuan market value proud to stand first.

Source: Oriental Fortune Network, the same below

If divided according to market value, the three echelon of Chinese pharmaceutical enterprises have been basically clear.

The first tier, that is, the market capitalization of more than 100 billion yuan in leading enterprises, led by Hengrui medicine, Kangmei Pharmaceutical, Fosun Pharma, Yunnanbaiyao has long been hundreds of billions of value clubs regulars.

As the saying goes: ironclad barrage of soldiers, in fact, billions of market value club the same, even assault rushed to this camp, can continue to maintain its position is not a small test.November 14, 2017, much attention Huada gene for the first time exceeded 100 billion market capitalization, reaching a peak of 102.8 billion, but then entered the shock period, as of the end of the statistics, the market value has dropped 800 billion range, 83.2 billion Shanghai Leshi the same, with blood Products for the main business and relying on the rapid rise of mergers and acquisitions Shanghai Lai Shi for a considerable period of time are hovering at the edge of the market value of billions, but with the controversy of the restructuring and reorganization into the decline in performance since 2017 into question, In the end, the market value of hundreds of billions of market capitals was eventually double. Compared with the market value of 114.7 billion by the end of 2016, the market value of Shanghai Leshi fell 13.95% to 98.7 billion yuan by the end of 2017.

Has been kept in the leading is Hengrui medicine November 3, according to the closing price of the day, Hengrui medicine market value reached 202.67 billion yuan, which is the first time in the history of Chinese medicine companies have exceeded 200 billion yuan market value mark. Boiling voice at the same time, in fact, did not feel too much surprise at this time, after all, as a rare set of innovative, international, generic drugs to enhance the concentration of the three major logical in one of the pharmaceutical companies, whether it is product line, R & D capabilities, cash flow have come to the fore, as the star of the capital market is also not surprising.

Kangmei Pharmaceutical is the official breakthrough in the market value of 100 billion on May 19, 2017, but also become the third company in the A-share pharmaceutical companies to break the market value of 100 billion. And the reason for this is because as a leader in the field of subdivision, Pharmaceutical has been in the upper and lower reaches have enough voice, whether it is upstream of Chinese herbal medicines, Chinese Herbal Pieces, or the middle of the sales circulation, or back-end hospital Pharmacies, Hong Mei Pharmaceutical have long been well laid out.

Shortly thereafter, on June 13, Yunnan Baiyao formally entered the billions of clubs with a market capitalization of 101.068 billion yuan, and at this time, it was just shortly before the end of the highly publicized Yunnan Baiyao mixed-play drama. Jiangsu Juyue heavily involved, have made this as early as 1993 restructuring of state-owned background of the listed companies rejuvenated a new vitality and its own solid strength, but also makes its market value of more than one hundred billion is a large probability event .

Fosun Pharma, meanwhile, was a completely new entrant and a rapidly emerging company with a market capitalization of only 55 billion yuan by the end of 2016, and almost doubled its growth by the end of 2017 111 billion yuan in the past year, Fosun Pharma has indeed continued to move: the acquisition of Indian generic drug company Gland has finally made substantial progress, with the establishment of Kite CAR-T Fosun Kate began CAR-T products in China Of the industrialization journey ... This investment-based company is catching up.

The second echelon, it is the market value of 50 billion to 100 billion in the enterprise in this list, located in this range of a total of nine, of which both established veteran manufacturers Baiyun Mountain, China Biopharmaceutical, etc., There are also recently broke the star Huada Gene, there are similar to the Sinopharm, medicine and other pharmaceutical distribution giants.

It can be said that these companies are now the mainstay of the development of China's pharmaceutical enterprises, the next one hundred billion market capitalization companies are likely to be born from which, in fact, as mentioned above, Shanghai Lai Shi and Huada gene are also topped 100 billion market capitalization However, the market value of bio-pharmaceuticals in China surpassed 100% in 2017, reaching 137.22%, which shows the momentum of development.

The third echelon, it is between 25 billion to 50 billion range of businesses.This time, Beida Pharmaceutical with a market value of 25.4 billion yuan in the top 500 companies in the whole industry rankings ranked No. 499, it is precisely because 25.4 billion will become The pharmaceutical companies short-listed the market value of 500 minimum threshold.

From the geographical point of view, the list of top enterprises in the distribution of the region is still the highest, which is up to Guangdong, of which up to six (Huada gene, Livzon Group, Baiyun Mountain, Hong Mei Pharmaceutical, Sinopharm Accord, China Resources Sanjiu); Shanghai Five (Fosun Pharma, Shanghai Pharmaceutical, Sinopharm Medicine, Goodyear Health), Beijing Four (Baekje Divine, Lepu Medical, China Medicine, Tong Ren Tang).

Of course, the advantages of mega cities do not need to go into details, policy, talent, transportation and other reasons, the choice of pharmaceutical companies played an important influence .But with other industries is different, the distribution of pharmaceutical companies really do not completely follow this rule , Some cities can hatch a big company instead of the big ones.Only Fosun Pharma is located in Shanghai, the other several headquarters are not big cities, such as Hengrui in Lianyungang, Jiangsu Province, also in Lianyungang But also includes a number of well-known pharmaceutical companies such as Jiangsu Howson, Chia Tai days fine; Kang Pharmaceutical headquarters is located in Puning, Guangdong, but now its scope of business and offices are also throughout the country; Yunnanbaiyao veteran state-owned enterprises, is located in Kunming, Yunnan, But the same did not affect its profound knowledge.

In addition, a number of unique pharmaceutical companies have also emerged in some regions, such as Pien Tze Huang in Zhangzhou, Fujian Province, with a market capitalization of 38.1 billion yuan in 2017, an increase of 38.02%. In the past few years, Affected by the tight supply of raw materials, the prices of Pien Tze Huang products are soaring along with the soaring prices of Dong Ya Ejiao, which is located in Dong'e County, Liaocheng City, Shandong Province. As a small county-based enterprise, its market capitalization reached 2017 39.4 billion yuan, an increase of 11.88%.

In 2017, the market capitalization rose the most, being Nasdaq-listed Chinese innovative pharmaceutical company: Baekje Shenzhou, with a total market capitalization of RMB29.1 billion in 2017, an increase of 318.24% over the same period of last year.

The reason is that the market capitalization is on the rise with the positive news of Baekjae Shenzhou in 2017. In September 2017, Baekje Shenzhou officially launched a global strategic cooperation with Shinchi, a world-renowned biopharmaceutical company, in the field of oncology in Beijing. In September 2017, Involving a total amount of 1.393 billion U.S. dollars, setting a new record for the transfer of rights and interests of domestic pharmaceutical companies and single species. Meanwhile, Baekje Shenzhou completed its first drug production base in Suzhou, China. There are two types of small molecule drugs that have been put into operation: BGB-3111 and BGB-290, respectively, for lymphomas and solid tumors In 2017, Baekje completed its leap from research and development to manufacturing and marketing to become a full-scale pharmaceutical company.

It is worth noting that the soaring market value of Baekje Shenzhou, one of the medium-sized stocks listed in the United States in the past two years, proves one thing that Chinese innovative pharmaceutical enterprises have gradually gained recognition in the international market. Following the pace of Baekje Shenzhou, In 2017, Re Ding Medicine has also been successfully listed in the United States. Recently, China Linkage Medicine and Cinda Bio also reported the IPO information. It is foreseeable that in the next few years, China's new drug research and development company will be on the international mainstream market Make more sounds.

For China's biopharmaceuticals, 2017 is also a year worth celebrating, an increase of 137.22% over the same period of last year, with almost all of Biosciences' products and sales reaching over one billion RMB. While its net profit surged , Management costs control is also better.China's bio-pharmaceutical research and development investment in early 2017 also bear fruit, the third quarter received two copies of the production license, five clinical approval, clinical application of the new 12 and declare the production of 6; Tenofovir is expected Hepatitis B indications were approved at the beginning of 2018; Innovative bio-drug TQB2450 injection (anti-PD-L1 monoclonal antibody) is likely to receive CFDA approval to conduct clinical trials during the year; Arotinib, lenalidomide, bendamust Ting, gefitinib these four varieties, the fastest will also be CFDA approved in 2018; apixaban, salmeterol truss powder inhalation and recombinant human coagulation factor Ⅷ with three Bidding The varieties are expected to be approved in 2019.

New and into is also full harvest, compared with the same period last year, an increase of 125.39% .To determine the main source of revenue increased production of methionine and flavors and fragrances prices, bringing great performance flexibility, the fourth quarter net profit of 5.42 ~ 9.03 100 million yuan. At the same time the first 50,000 tons of methionine project in the third quarter has reached production, the company methionine 100,000 tons production capacity has started construction is expected to put into operation in June to July 2019, 2021 three 150,000 tons production capacity will become The world's top four methionine enterprises.

But in the same way, a few happy and a few unhappy.Although most of the 42 companies on the list are the first increase in market value, but in 2017 there are a total of seven pharmaceutical companies market value has shrunk.Among them, especially in the step decline in the most serious pharmaceutical , Reaching 46.63%.

You know, at the close of December 30, 2016, Step Pharmaceuticals shares were 95.3 yuan / share, the total market value reached 65 billion yuan, and a year later, the step of the pharmaceutical shares fell to 50 yuan range, a year The market value has shrunk more than 30 billion yuan, and the stock price break.While the reason, with its huge risk inherent in the product layout itself is not unrelated, we all know, step long-term dependence on its three core products (Naoxintong capsule, Wenxin particles, Danhong injection) to maintain its performance, its marketing and high academic fees are also controversial in the current situation around the auxiliary medication have to strengthen monitoring, the market performance is indeed in a more awkward position.

While another star company Beida Pharmaceutical's market value is equally striking drop when relying on a burst drug The success of A-share market attracted numerous investors attention, but compared to nearly 30 billion market capitalization in 2016, the current Beida also shrunk 14.24% to 254 billion yuan, the reason is also due to this a burst of drugs. Icotinib almost 100% of Beida Pharmaceutical contributed revenue, a single dominance of the situation is very obvious, the risk of over-reliance on a single product is extremely vulnerable to the outbreak, which is why Beida Pharmaceutical has also been increased R & D efforts and mergers and acquisitions action.